Pub Date : 2023-11-06DOI: 10.24875/recice.m22000319
Clara Ugueto-Rodrigo, Alfonso Jurado-Román, Lucía Fernández-Gassó, Guillermo Galeote-García, and, Raúl Moreno
{"title":"Impella-Clip: a secure and effective strategy in cardiogenic shock due to acute severe mitral regurgitation. Case resolution","authors":"Clara Ugueto-Rodrigo, Alfonso Jurado-Román, Lucía Fernández-Gassó, Guillermo Galeote-García, and, Raúl Moreno","doi":"10.24875/recice.m22000319","DOIUrl":"https://doi.org/10.24875/recice.m22000319","url":null,"abstract":"","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":"23 27","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135545540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-06DOI: 10.24875/recice.m23000378
José M. de la Torre Hernández, Gabriela Veiga Fernández, Sergio Barrera, Fermín Sainz Laso, Dae-Hyun Lee, and Tamara García Camarero
{"title":"New TAVI technique for difficult valve crossing","authors":"José M. de la Torre Hernández, Gabriela Veiga Fernández, Sergio Barrera, Fermín Sainz Laso, Dae-Hyun Lee, and Tamara García Camarero","doi":"10.24875/recice.m23000378","DOIUrl":"https://doi.org/10.24875/recice.m23000378","url":null,"abstract":"","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":"6 14","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135584376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-06DOI: 10.24875/recice.m23000405
José M. de la Torre-Hernández, Fernando Alfonso, Raúl Moren, Soledad Ojeda, Armando Pérez de Prado, and, Rafael Romaguera
{"title":"Marking a milestone. REC: Interventional Cardiology assigned its first impact factor","authors":"José M. de la Torre-Hernández, Fernando Alfonso, Raúl Moren, Soledad Ojeda, Armando Pérez de Prado, and, Rafael Romaguera","doi":"10.24875/recice.m23000405","DOIUrl":"https://doi.org/10.24875/recice.m23000405","url":null,"abstract":"","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":"22 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135585431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-02DOI: 10.24875/recice.m23000415
Andrea Freixa-Benavente, Paola Dolader, Ferran Gran, and, Pedro Betrián-Blasc
Introduction and objectives : Although cardiac catheterization (CC) has become a routine practice in pediatric heart transplantation (HT), there is still a shortage of widely used protocols and strong evidence on the number of procedures required and their impact on HT outcomes, as well as the need for further CC. This study aimed to analyze CC activity in pediatric HT recipients in a tertiary center and describe risk factors for a higher number of post-HT procedures. Methods : This retrospective study obtained data from medical reports and image files. The sample was composed of patients with cardiomyopathies and congenital heart diseases (CHD). Risk factor analysis for CCs was conducted with linear regression and the ANOVA test. Results : The sample included 61 children (36.07% with CHD). The CHD group had a higher mean number of CCs prior to HT. The most frequent activities prior to HT were diagnostic catheterizations, followed by endomyocardial biopsies for cardiomyopathies and aortopulmonary collaterals in CHD patients. There were 389 post-HT CCs (608 procedures). Most CCs were performed for rejection surveillance, accounting for 92.75% of procedures. The univentricular CHD subgroup was associated with a higher number of CC after HT ( P = .03). Conclusions : Despite long life expectancy, pediatric HT recipients have substantial morbidity due to these procedures. Therefore, it is necessary to establish protocols for follow-up and rejection surveillance to minimize the interventions required by these patients.
{"title":"Cardiac catheterization activity in pediatric cardiac transplantation. Can catheterization needs be predicted?","authors":"Andrea Freixa-Benavente, Paola Dolader, Ferran Gran, and, Pedro Betrián-Blasc","doi":"10.24875/recice.m23000415","DOIUrl":"https://doi.org/10.24875/recice.m23000415","url":null,"abstract":"Introduction and objectives : Although cardiac catheterization (CC) has become a routine practice in pediatric heart transplantation (HT), there is still a shortage of widely used protocols and strong evidence on the number of procedures required and their impact on HT outcomes, as well as the need for further CC. This study aimed to analyze CC activity in pediatric HT recipients in a tertiary center and describe risk factors for a higher number of post-HT procedures. Methods : This retrospective study obtained data from medical reports and image files. The sample was composed of patients with cardiomyopathies and congenital heart diseases (CHD). Risk factor analysis for CCs was conducted with linear regression and the ANOVA test. Results : The sample included 61 children (36.07% with CHD). The CHD group had a higher mean number of CCs prior to HT. The most frequent activities prior to HT were diagnostic catheterizations, followed by endomyocardial biopsies for cardiomyopathies and aortopulmonary collaterals in CHD patients. There were 389 post-HT CCs (608 procedures). Most CCs were performed for rejection surveillance, accounting for 92.75% of procedures. The univentricular CHD subgroup was associated with a higher number of CC after HT ( P = .03). Conclusions : Despite long life expectancy, pediatric HT recipients have substantial morbidity due to these procedures. Therefore, it is necessary to establish protocols for follow-up and rejection surveillance to minimize the interventions required by these patients.","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":"8 20","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135973239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-30DOI: 10.24875/recice.m23000402
Diana Salas-Mera, César Abelleira Pardeiro, Enrique José Balbacid Domingo, Adolfo Sobrino Baladrón, José Luis Zunzunegui Martínez, Fernando Sarnago Cebada, and, Federico Gutiérrez-Larraya Aguado
Introduction and objectives: Surgery for congenital heart defects with right ventricular outflow tract (RVOT) stenosis often results in significant pulmonary regurgitation, requiring pulmonary valve replacement in the long term. Despite the development of balloon-expandable prostheses, the native RVOT frequently dilates beyond the maximum diameters allowed for these valves. To allow percutaneous pulmonary valve implantation (PPVI) in these patients, clinical trials have been initiated with self-expanding prostheses, including the PULSTA valve. The aim of this study was to report the initial experience with this valve at three Spanish hospitals. Methods: Descriptive study presenting the results of PPVI with the PULSTA prosthesis in patients with native RVOT and pulmonary regurgitation. Results: We included 10 patients with a mean age of 15 ± 2.8 years. The implantation was successful in all patients, with no major complications occurring during the procedure. The mean length of follow-up was 18 [range, 2-35] months. In 8 patients, cardiac magnetic resonance was performed at 6 months, revealing a reduction in mean end-diastolic volume (131.7 ± 31.7 mL/m 2 vs 100.3 ± 28.9 mL/m 2 ) and end-systolic volume (68 ± 20.8 mL/m 2 vs 57 ± 18.5 mL/m 2 ). Conclusions: The PULSTA prosthesis offers a safe, feasible, and effective alternative for PPVI in patients with native dilated RVOT. Due to the limited available follow-up data, further studies are needed to assess its long-term safety and durability.
{"title":"The PULSTA valve in native right ventricular outflow tract: initial experience in 3 Spanish hospitals","authors":"Diana Salas-Mera, César Abelleira Pardeiro, Enrique José Balbacid Domingo, Adolfo Sobrino Baladrón, José Luis Zunzunegui Martínez, Fernando Sarnago Cebada, and, Federico Gutiérrez-Larraya Aguado","doi":"10.24875/recice.m23000402","DOIUrl":"https://doi.org/10.24875/recice.m23000402","url":null,"abstract":"Introduction and objectives: Surgery for congenital heart defects with right ventricular outflow tract (RVOT) stenosis often results in significant pulmonary regurgitation, requiring pulmonary valve replacement in the long term. Despite the development of balloon-expandable prostheses, the native RVOT frequently dilates beyond the maximum diameters allowed for these valves. To allow percutaneous pulmonary valve implantation (PPVI) in these patients, clinical trials have been initiated with self-expanding prostheses, including the PULSTA valve. The aim of this study was to report the initial experience with this valve at three Spanish hospitals. Methods: Descriptive study presenting the results of PPVI with the PULSTA prosthesis in patients with native RVOT and pulmonary regurgitation. Results: We included 10 patients with a mean age of 15 ± 2.8 years. The implantation was successful in all patients, with no major complications occurring during the procedure. The mean length of follow-up was 18 [range, 2-35] months. In 8 patients, cardiac magnetic resonance was performed at 6 months, revealing a reduction in mean end-diastolic volume (131.7 ± 31.7 mL/m 2 vs 100.3 ± 28.9 mL/m 2 ) and end-systolic volume (68 ± 20.8 mL/m 2 vs 57 ± 18.5 mL/m 2 ). Conclusions: The PULSTA prosthesis offers a safe, feasible, and effective alternative for PPVI in patients with native dilated RVOT. Due to the limited available follow-up data, further studies are needed to assess its long-term safety and durability.","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":"115 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136068305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-30DOI: 10.24875/recice.m23000407
Luis Fernández González, Roberto Blanco Mata, Koldobika García San Román, Juan Carlos Astorga Burgo, Aída Acín Labarta, and, Josune Arriola Meabe
{"title":"Implantation of a pulmonary bioprosthetic valve in a single pulmonary artery","authors":"Luis Fernández González, Roberto Blanco Mata, Koldobika García San Román, Juan Carlos Astorga Burgo, Aída Acín Labarta, and, Josune Arriola Meabe","doi":"10.24875/recice.m23000407","DOIUrl":"https://doi.org/10.24875/recice.m23000407","url":null,"abstract":"","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":"28 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136068358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-23DOI: 10.24875/recice.m23000414
Carlos Coroas Pascual, Mikel Arrizabalaga Gil, Iván Olavarri Miguel, Carmen Garrote Coloma, Isaac Pascual Calleja, and José M. de la Torre-Hernández
{"title":"Impella-supported MitraClip implantation in acute mitral regurgitation","authors":"Carlos Coroas Pascual, Mikel Arrizabalaga Gil, Iván Olavarri Miguel, Carmen Garrote Coloma, Isaac Pascual Calleja, and José M. de la Torre-Hernández","doi":"10.24875/recice.m23000414","DOIUrl":"https://doi.org/10.24875/recice.m23000414","url":null,"abstract":"","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":"R-12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135368298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction and objectives: Contrast-induced-acute kidney injury (CI-AKI) is a potential complication of angiographic procedures. The DyeVert Contrast Reduction system (Osprey Medical, United States) is a device to reduce the concentration of contrast medium (CM) in the kidneys by decreasing the amount of CM delivered to patients. Unlike manual systems, few data are available on the DyeVert Power XT system, which is used in conjunction with automated contrast injection. The main aim of our study was to evaluate its effectiveness during percutaneous coronary interventions (PCI). Methods: Between 2020 and 2022, 101 patients who underwent PCI with the DyeVert Power XT system (case group) were enrolled to evaluate the amount of CM saved through the use of this device, as well as the rate, severity, and predictors of CI-AKI. Patients who underwent PCI without the use of the device (control group) were enrolled to create a matched group allowing assessment of differences in CM and the CI-AKI rate. Results : In the case group, the amount of CM saved was 114 ± 42 mL, representing an average of 32% of the total CM. Fourteen patients (13.9%) developed CI-AKI. The only independent predictors of CI-AKI were hematocrit (OR, 0.86; 95%CI, 0.74-0.99; P = .04) and ejection fraction (OR, 0.88; 95%CI, 0.82-0.95; P = .001). As a result of diversion by the device, the amount of CM delivered was lower in the case group than in controls (252 vs 267 mL; P = .42), but this difference was nonsignificant. Equally, the reduction in CI-AKI (14.3% vs 16.3%) was nonsignificant. Conclusions: Hematocrit and ejection fraction may be more important predictors of CI-AKI than the CM volume normally used during PCI in the general population. The net practical benefit of DyeVert Power XT was low.
{"title":"Effectiveness of the DyeVert Power XT system during percutaneous coronary interventions","authors":"Federico Vergni, Manfredi Arioti, Valentina Boasi, Federico Ariel Sánchez, Massimo Leoncini and, Fabio Ferrari","doi":"10.24875/recice.m23000409","DOIUrl":"https://doi.org/10.24875/recice.m23000409","url":null,"abstract":"Introduction and objectives: Contrast-induced-acute kidney injury (CI-AKI) is a potential complication of angiographic procedures. The DyeVert Contrast Reduction system (Osprey Medical, United States) is a device to reduce the concentration of contrast medium (CM) in the kidneys by decreasing the amount of CM delivered to patients. Unlike manual systems, few data are available on the DyeVert Power XT system, which is used in conjunction with automated contrast injection. The main aim of our study was to evaluate its effectiveness during percutaneous coronary interventions (PCI). Methods: Between 2020 and 2022, 101 patients who underwent PCI with the DyeVert Power XT system (case group) were enrolled to evaluate the amount of CM saved through the use of this device, as well as the rate, severity, and predictors of CI-AKI. Patients who underwent PCI without the use of the device (control group) were enrolled to create a matched group allowing assessment of differences in CM and the CI-AKI rate. Results : In the case group, the amount of CM saved was 114 ± 42 mL, representing an average of 32% of the total CM. Fourteen patients (13.9%) developed CI-AKI. The only independent predictors of CI-AKI were hematocrit (OR, 0.86; 95%CI, 0.74-0.99; P = .04) and ejection fraction (OR, 0.88; 95%CI, 0.82-0.95; P = .001). As a result of diversion by the device, the amount of CM delivered was lower in the case group than in controls (252 vs 267 mL; P = .42), but this difference was nonsignificant. Equally, the reduction in CI-AKI (14.3% vs 16.3%) was nonsignificant. Conclusions: Hematocrit and ejection fraction may be more important predictors of CI-AKI than the CM volume normally used during PCI in the general population. The net practical benefit of DyeVert Power XT was low.","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":"84 2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135368669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-23DOI: 10.24875/recice.m23000404
Juan M. Ruiz-Nodar, and Javier Pineda Rocamora
{"title":"Vascular closure devices: the jury is still out","authors":"Juan M. Ruiz-Nodar, and Javier Pineda Rocamora","doi":"10.24875/recice.m23000404","DOIUrl":"https://doi.org/10.24875/recice.m23000404","url":null,"abstract":"","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":"65 6","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135413435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-18DOI: 10.24875/recice.m23000403
Ángel Manuel Iniesta Manjavacas
stable patients with ischemic dilated cardiomyopathy to undergo percutaneous coronary
{"title":"Debate. Percutaneous revascularization in dilated cardiomyopathy. Apropos of the REVIVED BCIS2 trial: the clinician�s view","authors":"Ángel Manuel Iniesta Manjavacas","doi":"10.24875/recice.m23000403","DOIUrl":"https://doi.org/10.24875/recice.m23000403","url":null,"abstract":"stable patients with ischemic dilated cardiomyopathy to undergo percutaneous coronary","PeriodicalId":34613,"journal":{"name":"REC Interventional Cardiology English Ed","volume":"200 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135824022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：